Drug Overview
Savaysa (edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Inhibition of factor Xa reduces thrombin generation and thrombus formation. Savaysa inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.
Savaysa is also indicated for stroke prevention in atrial fibrillation.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Savaysa : Stroke prevention in atrial fibrillation (SPAF)
20 Savaysa : Venous thromboembolism (VTE)
LIST OF FIGURES
13 Figure 1: Savaysa for SPAF – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Savaysa for SPAF
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Savaysa for SPAF
17 Figure 4: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country, 2017–26
26 Figure 5: Savaysa for venous thromboembolism – SWOT analysis
27 Figure 6: Datamonitor Healthcare’s drug assessment summary of Savaysa for venous thromboembolism
28 Figure 7: Datamonitor Healthcare’s drug assessment summary Savaysa for venous thromboembolism
30 Figure 8: Savaysa sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Savaysa drug profile
7 Table 2: Savaysa pivotal trial data in SPAF
9 Table 3: Savaysa late-phase trial data in SPAF
11 Table 4: Savaysa ongoing late-phase clinical trials in SPAF
18 Table 5: Savaysa sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 6: Savaysa drug profile
22 Table 7: Savaysa pivotal trial data in venous thromboembolism
24 Table 8: Savaysa late-phase trial data in venous thromboembolism
25 Table 9: Savaysa ongoing late-phase clinical trial in venous thromboembolism
31 Table 10: Savaysa sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017–26